Ceftolozane/tazobactam – the «new player» in a battle against multiresistant pathogens

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(4):354-361

Type
Journal article

Abstract

Ceftolozane/tazobactam is a new combined antibacterial agent for the treatment of infections caused by gram-negative microorganisms, P. aeruginosa in particular, including strains resistant to other clinically available antimicrobials. In this paper we reviewed the data on antimicrobial activity, pharmacokinetics, clinical efficacy and safety of ceftolozane/tazobactam, as well as its potential role for the treatment of complicated intra-abdominal infections and urinary tract infections.

Views
0 Abstract
0 PDF
0 BibTeX
Shared
0
0
0
0
0
0